Personalized vascular medicine: individualizing drug therapy

about

Personalized medicine in cardiovascular diseases.High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.Pharmacogenomics of oral antiplatelet drugs.

P2860

Q36306729-A02DF78C-3267-40A3-A7EC-029B7A90E637 Q36328889-8539AAD5-1371-4719-9D64-C2D62B5445F6 Q38161868-9F2BC434-09CF-4F82-8ACD-1F82A10B9A68 Q38195628-A942E572-4299-46B7-A426-442C1092D4FB

P2860

Personalized vascular medicine: individualizing drug therapy

Item

http://www.wikidata.org/entity/Q37142852

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Personalized vascular medicine: individualizing drug therapy

@en

Personalized vascular medicine: individualizing drug therapy.

@nl

type

Item

label

Personalized vascular medicine: individualizing drug therapy

@en

Personalized vascular medicine: individualizing drug therapy.

@nl

prefLabel

Personalized vascular medicine: individualizing drug therapy

@en

Personalized vascular medicine: individualizing drug therapy.

@nl

P1476

Personalized vascular medicine: individualizing drug therapy

@en

P2093

Emil M Degoma

http://www.w3.org/2001/XMLSchema#string

Emile R Mohler

http://www.w3.org/2001/XMLSchema#string

Giovanni Rivera

http://www.w3.org/2001/XMLSchema#string

M Haris U Usman

http://www.w3.org/2001/XMLSchema#string

Scott M Lilly

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

Early and late effects of clopidogrel in patients with acute coronary syndromes

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

P304

391-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1358863X11422251

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22003003

http://www.w3.org/2001/XMLSchema#string

P932

3761360

http://www.w3.org/2001/XMLSchema#string

Personalized vascular medicine: individualizing drug therapy

about

P2860

P2860

Personalized vascular medicine: individualizing drug therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932